Delta radiomics: an updated systematic review
La radiologia medica · 17.07.2024 · 129 (8) · 1197-1214
DOI: 10.1007/s11547-024-01853-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift La radiologia medica, online erschienen am 17.07.2024. Verfasst von Valerio Nardone und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138, Naples, Italy. Valerio.nardone@unicampania.it. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi della Campania Luigi Vanvitelli.
Abstract (Originalsprache)
Background
Radiomics can provide quantitative features from medical imaging that can be correlated with various biological features and diverse clinical endpoints. Delta radiomics, on the other hand, consists in the analysis of feature variation at different acquisition time points, usually before and after therapy. The aim of this study was to provide a systematic review of the different delta radiomics approaches.
Methods
Eligible articles were searched in Embase, Pubmed, and ScienceDirect using a search string that included free text and/or Medical Subject Headings (MeSH) with 3 key search terms: 'radiomics,' 'texture,' and 'delta.' Studies were analyzed using QUADAS-2 and the RQS tool.
Results
Forty-eight studies were finally included. The studies were divided into preclinical/methodological (5 studies, 10.4%); rectal cancer (6 studies, 12.5%); lung cancer (12 studies, 25%); sarcoma (5 studies, 10.4%); prostate cancer (3 studies, 6.3%), head and neck cancer (6 studies, 12.5%); gastrointestinal malignancies excluding rectum (7 studies, 14.6%) and other disease sites (4 studies, 8.3%). The median RQS of all studies was 25% (mean 21% ± 12%), with 13 studies (30.2%) achieving a quality score < 10% and 22 studies (51.2%) < 25%.
Conclusions
Delta radiomics shows potential benefit for several clinical endpoints in oncology, such asdifferential diagnosis, prognosis and prediction of treatment response, evaluation of side effects. Nevertheless, the studies included in this systematic review suffer from the bias of overall low methodological rigor, so that the conclusions are currently heterogeneous, not robust and hardly replicable. Further research with prospective and multicenter studies is needed for the clinical validation of delta radiomics approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138, Naples, Italy. Valerio.nardone@unicampania.it.
- Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138, Naples, Italy.
- Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
- Department of Biomedical, Experimental and Clinical Sciences "M. Serio", University of Florence, Florence, Italy.
Förderung
- Università degli Studi della Campania Luigi Vanvitelli
Zitieren
APA
Nardone, V., Reginelli, A., Rubini, D., Gagliardi, F., Del Tufo, S., Belfiore, M. P., Boldrini, L., Desideri, I., & Cappabianca, S. (2024). Delta radiomics: an updated systematic review. La radiologia medica, 129(8), 1197-1214. https://doi.org/10.1007/s11547-024-01853-4
Vancouver
Nardone V, Reginelli A, Rubini D, Gagliardi F, Del Tufo S, Belfiore MP, et al. Delta radiomics: an updated systematic review. La radiologia medica. 2024;129(8):1197-1214. doi:10.1007/s11547-024-01853-4
BibTeX
@article{Nardone2024,
author = {Nardone, Valerio and Reginelli, Alfonso and Rubini, Dino and Gagliardi, Federico and Del Tufo, Sara and Belfiore, Maria Paola and Boldrini, Luca and Desideri, Isacco and Cappabianca, Salvatore},
title = {Delta radiomics: an updated systematic review},
journal = {La radiologia medica},
year = {2024},
volume = {129},
number = {8},
pages = {1197--1214},
doi = {10.1007/s11547-024-01853-4}
}
EUVIMED